News

Qilu Pharmaceutical recognized as Top 3 domestic R&D pharmaceutical company of 2019

ABOUT US

News

Qilu Pharmaceutical recognized as Top 3 domestic R&D pharmaceutical company of 2019

Release time：

2019-06-22

Jun 21^th, 2019, China Medical & Health Industry Development Conference and the 4^th China Pharmaceutical R&D Summit” (PDI) was held at the International Exhibition Center in Chongqing. Qilu Pharmaceutical was honored as Top 3 Chinese R&D pharmaceutical company based on its comprehensive capability in the industry.

Qilu Pharmaceutical Ranks No. 8th among Top 100 Chinese Pharmaceutical Companies

Qilu Pharma Announces Launch of a Generic Version of Vesicare® in the United States

Related News

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”